343 related articles for article (PubMed ID: 10654892)
1. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia.
Mikolajczyk SD; Millar LS; Wang TJ; Rittenhouse HG; Wolfert RL; Marks LS; Song W; Wheeler TM; Slawin KM
Urology; 2000 Jan; 55(1):41-5. PubMed ID: 10654892
[TBL] [Abstract][Full Text] [Related]
2. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
3. Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia.
Mikolajczyk SD; Millar LS; Marker KM; Wang TJ; Rittenhouse HG; Marks LS; Slawin KM
Prostate; 2000 Nov; 45(3):271-6. PubMed ID: 11074531
[TBL] [Abstract][Full Text] [Related]
4. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.
Mikolajczyk SD; Millar LS; Wang TJ; Rittenhouse HG; Marks LS; Song W; Wheeler TM; Slawin KM
Cancer Res; 2000 Feb; 60(3):756-9. PubMed ID: 10676664
[TBL] [Abstract][Full Text] [Related]
5. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia.
Slawin KM; Shariat S; Canto E
Rev Urol; 2005; 7 Suppl 8(Suppl 8):S52-6. PubMed ID: 16985891
[TBL] [Abstract][Full Text] [Related]
6. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease.
Linton HJ; Marks LS; Millar LS; Knott CL; Rittenhouse HG; Mikolajczyk SD
Clin Chem; 2003 Feb; 49(2):253-9. PubMed ID: 12560348
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of prostate-specific antigen in the transition zone of the prostate. A characterization following prostatectomy for benign hyperplasia.
Recker F; Kwiatkowski MK; Pettersson K; Piironen T; Lümmen G; Huber A; Tscholl R
Eur Urol; 1998; 33(6):549-55. PubMed ID: 9743696
[TBL] [Abstract][Full Text] [Related]
8. Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies.
Wang TJ; Slawin KM; Rittenhouse HG; Millar LS; Mikolajczyk SD
Eur J Biochem; 2000 Jul; 267(13):4040-5. PubMed ID: 10866804
[TBL] [Abstract][Full Text] [Related]
9. Role of the transition zone for elevating serum prostate-specific antigen in benign prostatic hyperplasia.
Sakamoto W; Iwata H; Kamikawa S; Tsurusaki K; Sugimoto T; Nakatani T; Sugimura K; Yamamoto K; Kishimoto T
Int J Urol; 1998 Mar; 5(2):163-6. PubMed ID: 9559843
[TBL] [Abstract][Full Text] [Related]
10. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.
Chen Z; Chen H; Stamey TA
J Urol; 1997 Jun; 157(6):2166-70. PubMed ID: 9146608
[TBL] [Abstract][Full Text] [Related]
12. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels.
Lepor H; Wang B; Shapiro E
Urology; 1994 Aug; 44(2):199-205. PubMed ID: 7519380
[TBL] [Abstract][Full Text] [Related]
13. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
15. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
16. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia.
Björk T; Bjartell A; Abrahamsson PA; Hulkko S; di Sant'Agnese A; Lilja H
Urology; 1994 Apr; 43(4):427-34. PubMed ID: 7512295
[TBL] [Abstract][Full Text] [Related]
17. TRAF6 regulates proliferation of stromal cells in the transition and peripheral zones of benign prostatic hyperplasia via Akt/mTOR signaling.
Shi YF; Yu DJ; Jiang CY; Wang XJ; Zhu YP; Zhao RZ; Lv Z; Sun XW
Prostate; 2018 Feb; 78(3):193-201. PubMed ID: 29171041
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological study of prostate cancer patients who had a serum PSA level of more than 20 ng/ml and were treated by a radical prostatectomy].
Udo K; Otsubo S; Sakamoto N; Iguchi A
Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):685-90. PubMed ID: 17682447
[TBL] [Abstract][Full Text] [Related]
19. Does benign prostatic hyperplasia originate from the peripheral zone of the prostate? A preliminary study.
Tang J; Yang JC; Zhang Y; Liu X; Zhang L; Wang Z; Li J; Luo Y; Xu J; Shi H
BJU Int; 2007 Nov; 100(5):1091-6. PubMed ID: 17922787
[TBL] [Abstract][Full Text] [Related]
20. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
Mikolajczyk SD; Rittenhouse HG
Keio J Med; 2003 Jun; 52(2):86-91. PubMed ID: 12862359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
